$381.89
1.98% today
Nasdaq, Aug 12, 07:44 pm CET
ISIN
US92532F1003
Symbol
VRTX

Vertex Pharmaceuticals Stock price

$374.46
-94.39 20.13% 1M
-80.76 17.74% 6M
-28.24 7.01% YTD
-90.05 19.39% 1Y
+82.30 28.17% 3Y
+112.60 43.00% 5Y
+238.59 175.60% 10Y
+357.89 2,159.87% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+7.92 2.16%
ISIN
US92532F1003
Symbol
VRTX
Industry

Key metrics

Basic
Market capitalization
$96.3b
Enterprise Value
$89.9b
Net debt
-
Cash
$6.4b
Shares outstanding
256.3m
Valuation (TTM | estimate)
P/E
26.7 | 20.5
P/S
8.4 | 7.9
EV/Sales
7.9 | 7.4
EV/FCF
25.7
P/B
5.6
Financial Health
Equity Ratio
72.8%
Return on Equity
-3.3%
ROCE
22.3%
ROIC
27.2%
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$11.4b | $12.2b
EBITDA
$4.6b | $5.5b
EBIT
$4.4b | $5.4b
Net Income
$3.6b | $4.7b
Free Cash Flow
$3.5b
Growth (TTM | estimate)
Revenue
10.5% | 10.4%
EBITDA
3.8% | 19.9%
EBIT
4.2% | 22.8%
Net Income
842.5% | 975.9%
Free Cash Flow
345.5%
Margin (TTM | estimate)
Gross
86.1%
EBITDA
40.5% | 45.4%
EBIT
38.8%
Net
31.9% | 38.6%
Free Cash Flow
30.7%
More
EPS
$14.0
FCF per Share
$13.7
Short interest
1.8%
Employees
6k
Rev per Employee
$1.8m
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

40 Analysts have issued a Vertex Pharmaceuticals forecast:

24x Buy
60%
15x Hold
38%
1x Sell
3%

Analyst Opinions

40 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
60%
Hold
38%
Sell
3%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
11,419 11,419
10% 10%
100%
- Direct Costs 1,587 1,587
13% 13%
14%
9,832 9,832
10% 10%
86%
- Selling and Administrative Expenses 1,570 1,570
17% 17%
14%
- Research and Development Expense 3,833 3,833
13% 13%
34%
4,627 4,627
4% 4%
41%
- Depreciation and Amortization 200 200
4% 4%
2%
EBIT (Operating Income) EBIT 4,427 4,427
4% 4%
39%
Net Profit 3,638 3,638
843% 843%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
Seeking Alpha
about 21 hours ago
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable v...
Positive
The Motley Fool
3 days ago
What does it take to qualify as a growth stock? Probably the most important criterion is that the stock must be expected to grow significantly faster than the overall market.
Positive
The Motley Fool
4 days ago
It's been an excellent summer for the broader stock market, with the major indexes hovering around all-time highs and strong earnings from many top companies.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today